logo

Seres Therapeutics, Inc. (MCRB)



Trade MCRB now with
  Date
  Headline
9/7/2022 7:11:19 AM Seres Therapeutics Completes Rolling BLA Submission To FDA For SER-109 For Recurrent C. Difficile Infection
8/3/2022 7:10:43 AM Seres Therapeutics Q2 Net Loss Widens To $64.7 Mln From $48.3 Mln Last Year
6/30/2022 7:33:47 AM Seres Therapeutics Announces $100 Mln Registered Direct Offering Of Common Stock At $3.15/Shr
5/4/2022 7:16:11 AM Seres Therapeutics Q1 Net Loss $56.6 Mln Vs. Net Loss $35.5 Mln Last Year
3/18/2022 7:08:16 AM Seres Therapeutics To Present Preclinical Research On Microbiome Therapeutic SER-155 At The 2022 EMBT Annual Meeting
2/8/2022 7:03:28 AM Seres Therapeutics Appoints Paula Cloghessy As EVP, Chief People Officer
12/16/2021 7:16:10 AM Seres Reports Preliminary Microbiome Data Analyses From Phase 2b ECO-RESET Study Of SER-287 In Ulcerative Colitis
11/30/2021 7:04:42 AM Seres Therapeutics Enrolls First Patient In SER-155 Phase 1b Study
11/10/2021 2:17:20 AM Bacthera, Seres Collaborate For Commercial Manufacturing Of SER-109, Treatment Against Recurrent C. Difficile Infection
10/26/2021 7:14:40 AM Seres Presents Phase 3 Data On Investigational Microbiome Therapeutic SER-109 In Recurrent C. Difficile Infection
9/15/2021 7:07:05 AM Seres Therapeutics Enrolls 300 Subjects With Phase 3 ECOSPOR IV Open-Label Extension Study Of SER-109
8/3/2021 7:27:29 AM Seres Therapeutics Q2 Net Loss $48.3 Mln Vs. Net Loss Of $20.7 Mln Prior Year
7/1/2021 7:09:35 AM Seres Therapeutics, Nestl Health Science Unveil SER-109 Co-Commercialization License Deal